Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tissue-Agnostic Approach To Cancer Drug Development Takes A Hit

Executive Summary

Roche's VE-BASKET trial based treatment on biomarkers instead of the tissue of origin, but it ended up reinforcing the importance of conventional tumor histology in drug development as a complement to new molecularly targeted approaches. Now, eyes are on Novartis' ambitious SIGNATURE program to confirm the signal-finding potential of the basket trial approach.

Advertisement

Related Content

Master Protocols In Practice
Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development
Oncology: Tissue-Agnostic Indications Advance Under US FDA's Breakthrough Umbrella
Keytruda Approval Opens New Routes For Immuno-Oncology
I-SPY 2 Helping To Normalize Adaptive Trial Designs
The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057116

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel